Jason Marrone

Alta Partners Management Co. LP (Alta Partners) is a venture capital firm founded in 1996 by Jean Deleage, Guy Paul Nohra, Marino Polestra and Garrett P. Gruener. The firm is headquartered in Jackson, Wyoming.

Circadia Ventures LLP (Circadia Ventures) is a venture capital firm founded in 2006 by Simon A Barnes. Headquartered in London, United Kingdom.

Novome Biotechnologies, Inc. operates as a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The company was founded by William DeLoache, Weston Whitaker, Liz Shepherd and Zachary Russ in 2016 and is headquartered in South San Francisco, CA.

CuraSen Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapies to treat neurodegenerative diseases, including parkinson, alzheimer, and less common neurodegenerative disorders. The company was founded by Mehrdad Shamloo, Robert Booth, Anthony Ford, and Kathleen Sereda in 2018 and is headquartered in San Mateo, CA.

Lassen Therapeutics LLC operates as a therapeutic antibody company. It discovers and develops novel medicines to treat serious unmet medical needs. The company is headquartered in San Diego, CA.

Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded in March 1991 and is headquartered in Pleasanton, CA.

Be Biopharma, Inc. develops engineered B cells as a new category of cellular medicines. The company was founded by David Steinberg, Aleks Radovic-Moreno and Lea Hachigian and is headquartered in Cambridge, MA.

ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021.

Array Ventures (Array Ventures) is a venture capital firm founded in 2015 by Shruti Gandhi. The firm is headquartered in San Francisco, California.

DEM BioPharma, Inc. is an American company that pioneers the next generation of immunotherapeutics to eliminate tumors by targeting 'don't eat me' and 'eat me' signals on cancer cells, macrophages, and other myeloid effector cells. The company is based in Cambridge, MA. The proprietary CHOMP™ platform utilizes CRISPR-based functional genomic screens to discover and validate new signals that could enhance cancer cell elimination through increased phagocytosis. The company was founded by Longwood Fund and builds on groundbreaking functional genomics research and discoveries in macrophage biology from its scientific co-founders. Nenad Grmusa has been the CEO of the company since 2022.

Advanced BioNutrition Corp. provides environmentally sustainable and science-based technology solutions. It develops biotech products for animal health and human nutrition. The firm’s technologies include applications patents, licensing and acquisitions. The company was founded by David J. Kyle in 2001 and is headquartered in Columbia, MD.

Manna Tree Partners LLC (Manna Partners) is a venture capital firm founded in 2018 by Ellie Rubenstein, Ross Iverson and Brent Drever. The firm is headquartered in Vail, Colorado.

Lumora Ltd. provides molecular diagnostic products for the clinical and industrial markets. The company was founded by Laurence Carlo Tisi and James A. H. Murray in 2002 and is headquartered in Cambridge, the United Kingdom.

The California Academy of Sciences operates as a scientific and cultural institution. The Academy houses an aquarium, a planetarium a natural history museum and a rainforest. It was founded in 1853 and is headquartered in San Francisco, CA.

Previvo Genetics, Inc. provides medical device. The firms develops Previvo Uterine Lavage System, an equipment for pre-implantation genetic testing. The company was founded by John E. Buster and Steven K. Buster in 2012 and is headquartered in Parker, CO.

CoTherix, Inc. develops therapeutic products. Its ventavis product is a nebulizer delivered therapy for pulmonary artery hypertension, which restricts blood flow to the lungs. CoTherix markets its products in the US, Europe, and Australia. The company was founded in February, 2000 by Donald J. Santel and Gerard Turino and is located in Brisbane, CA.

Bankers Trust Co. is an asset management headquartered in Des Moines, Iowa. The firm was founded in 1917 and is a subsidiary of BTC Financial Corp. The firm serves as a trusted partner for individuals’ comprehensive financial planning, trust and fiduciary needs.

Acureon Pharmaceuticals, Inc. develops and markets therapeutics for infectious diseases. The firm’s synergistic combination of anti-infective expertise, dedicated clinical operations, marketing know-how and intellectual property, all coupled with well documented low attrition rates for anti-infective should translate into multiple product opportunities with a lower risk of failure, more rapid development timelines and early substantial returns on investment. The company was founded by Giorgio Mosconi in 2006 and is headquartered in Berwyn, PA.

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies